The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study

阿帕蒂尼 医学 肝细胞癌 内科学 联合疗法 胃肠病学 不利影响 肿瘤科 酪氨酸激酶抑制剂 实体瘤疗效评价标准 肝癌 无进展生存期 癌症 化疗 临床研究阶段
作者
Zeran Yang,Guang Chen,Ye Cui,Xiao Guo-wen,Ting Su,Jianan Yu,Zhiyuan Zhang,Yanjing Han,Kai-Lan Yang,Long Jin
出处
期刊:Cancer Biology & Therapy [Informa]
卷期号:20 (3): 321-327 被引量:34
标识
DOI:10.1080/15384047.2018.1529099
摘要

As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI), apatinib has a certain anti-tumor effect for a variety of solid tumors. The present study evaluates its efficacy and safety in advanced hepatocellular carcinoma (HCC). In this study, 47 patients with advanced HCC were included. TACE monotherapy group included 22 patients that responded to TACE, while the group that received TACE and apatinib included 25 patients that progressed on TACE and were able to receive apatinib off label. Median overall survival (OS) was significantly improved in the apatinib plus TACE group compared with the TACE group. Similarly, apatinib in combination with TACE significantly prolonged median progression-free survival (PFS) compared with TACE monotherapy. Furthermore, there was a significant difference between combination therapy and monotherapy in both Barcelona clinic liver cancer (BCLC) B and BCLC C group. The combination therapy had a dramatic effect on OS and PFS for patients at both BCLC B and BCLC C level. The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. The efficacy analysis showed that there was no significant association of survival benefit with age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension and hand-foot syndrome. Patients with macrovascular invasion and extrahepatic invasion showed worse survival benefits. In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
周芷卉完成签到 ,获得积分10
2秒前
甜美三娘完成签到,获得积分10
3秒前
左辄完成签到 ,获得积分10
8秒前
美满的皮卡丘完成签到 ,获得积分10
12秒前
yzxzdm完成签到 ,获得积分0
12秒前
chemist229完成签到 ,获得积分10
14秒前
geohr完成签到 ,获得积分10
17秒前
Deila完成签到 ,获得积分0
19秒前
Evan完成签到 ,获得积分10
21秒前
ghost完成签到 ,获得积分10
23秒前
plum完成签到 ,获得积分10
27秒前
乱世才子完成签到,获得积分10
29秒前
瘦瘦完成签到,获得积分10
32秒前
小蘑菇应助科研通管家采纳,获得10
35秒前
Lucas应助科研通管家采纳,获得10
35秒前
科研通AI2S应助Yimi采纳,获得10
38秒前
一颗红葡萄完成签到 ,获得积分10
39秒前
勤恳的书文完成签到 ,获得积分10
42秒前
卖鱼的乌鸦完成签到,获得积分10
46秒前
阿托伐他汀完成签到 ,获得积分10
49秒前
54秒前
hhh2018687完成签到,获得积分10
1分钟前
wBw完成签到,获得积分10
1分钟前
执着晓亦完成签到 ,获得积分10
1分钟前
1分钟前
taipingyang完成签到,获得积分10
1分钟前
红箭烟雨发布了新的文献求助10
1分钟前
kangshuai完成签到,获得积分10
1分钟前
August完成签到,获得积分10
1分钟前
斗鱼飞鸟和俞完成签到,获得积分10
1分钟前
毛毛完成签到,获得积分10
1分钟前
1分钟前
pwang_ecust完成签到,获得积分10
1分钟前
看文献完成签到,获得积分10
1分钟前
我的副本完成签到,获得积分10
1分钟前
末末发布了新的文献求助10
1分钟前
wangsai完成签到,获得积分10
1分钟前
秀丽的皮皮虾完成签到 ,获得积分10
1分钟前
zxcharm完成签到,获得积分10
1分钟前
新奇完成签到 ,获得积分10
2分钟前
高分求助中
Spray / Wall-interaction Modelling by Dimensionless Data Analysis 2000
Mathematics and Finite Element Discretizations of Incompressible Navier—Stokes Flows 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
2-Acetyl-1-pyrroline: an important aroma component of cooked rice 500
A real-time energy management strategy based on fuzzy control and ECMS for PHEVs 400
Handbook on People's China (1957) 400
2024 Medicinal Chemistry Reviews 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3190111
求助须知:如何正确求助?哪些是违规求助? 2839411
关于积分的说明 8023528
捐赠科研通 2502244
什么是DOI,文献DOI怎么找? 1336398
科研通“疑难数据库(出版商)”最低求助积分说明 637841
邀请新用户注册赠送积分活动 605974